Basal/triple negative breast cancer;Das tripelnegative/basale Mammakarzinom

Geburtshilfe und Frauenheilkunde

Volumn 69, Issue 4, 2009, Pages 309-315

  Liedtke, C ^a   Kiesel, L ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Basal; Breast cancer; Neoadjuvant chemotherapy; Targeted therapy; Triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; BEVACIZUMAB; BRCA1 PROTEIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN;

ADJUVANT CHEMOTHERAPY; AFRICAN AMERICAN; BREAST CANCER; CANCER RECURRENCE; CANCER RESEARCH; CANCER RISK; CAUCASIAN; DRUG PROTEIN BINDING; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; MASTECTOMY; MENARCHE; MULTIPARA; OBESITY; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TAXONOMY; TRIPLE NEGATIVE BREAST CANCER;

EID: 77149133761     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0029-1185548     Document Type: Review

References (28)

1. Forbes JF, Cuzick J, Buzdar A et al., Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists? Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53
2. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334
3. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502
4. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434
5. Early Breast Cancer Trialists? Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
6. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921
7. Fernández-Sánchez M, Gamboa-Dominguez A, Uribe N et al. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol 2006; 23: 171-183
8. Finn RS, Dering J, Ginther C et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007; 105: 319-326
9. Gluz O, Nitz UA, Harbeck N et al.,West German Study Group. Triple-negative high-risk breast cancer drives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol 2008; 19: 861-870
10. Goldhirsch A, Wood WC, Gelber RD et al., 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18: 1133-1144
11. Haffty BG, Yang Q, Reiss M et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652-5657
12. Hayes DF, Thor AD, Dressler LG et al., Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496-1506
13. Hess KR, Pusztai L, Buzdar AU et al. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003; 78: 105-118
14. Hoadley KA, Weigman VJ, Fan C et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics. 2007; 8: 258
15. Imkampe A, Bendall S, Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur J Surg Oncol 2007; 33: 420-423
16. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659-1668
17. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281
18. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676
19. Millikan RC, Newman B, Tse CK et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109: 123-139
20. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752
21. Piccart-GebhartMJ, Procter M, Leyland-Jones B et al., Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672
22. Rastogi P, Anderson SJ, Bear HD et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26: 778-785. Erratum in: J Clin Oncol 2008; 26: 2793
23. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684
24. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685
25. Ruckhäberle E, Rody A, Kaufmann M. Kongressbericht zur 44. Jahrestagung der American Society of Clinical Oncology, Chicago 30.5.- 3. 6.2008. Onkologische Therapie im Wandel - gerät die Chemotherapie an ihre Grenzen? Geburtsh Frauenheilk 2008; 68: 889-895
26. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792
27. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874
28. Sørlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423